Cinnabar Bracket

Metadata

Regulatory Status

Australia

• Australian Aboriginal peoples used Pycnoporus species (including the closely related P. sanguineus) traditionally for treating sore mouths and lips, representing one of the few documented ethnomedicinal uses of this genus
• Not listed in the Australian Therapeutic Goods Administration database as a registered medicine or listed product

United States

• Not marketed as a dietary supplement
• No FDA GRAS status
• Primarily studied for biotechnological applications (laccase-mediated bioremediation, dye decolorization) rather than medicinal use
• No NIH-funded clinical research for human health applications

European Union

• Not assessed under EU Novel Food Regulation (EU) 2015/2283
• No EMA/HMPC monograph
• Extensively studied in European laboratories (particularly in France) for its laccase enzymes and biotechnological applications
• The French National Institute for Agricultural Research (INRA) has conducted significant research on P. cinnabarinus laccase

China and Japan

• Not listed in the Chinese Pharmacopoeia or Japanese Pharmacopoeia
• No traditional use documented in East Asian medicine systems
• Some research on the genus Pycnoporus conducted at Chinese and Japanese institutions

Conditions & Indications

Primary (Preclinical Evidence)

• Bacterial infections (in vitro) — Cinnabarinic acid produced by P. cinnabarinus demonstrates potent antibacterial activity, with maximal inhibitory effect against Gram-positive bacteria of the genus Streptococcus. The concentrated culture fluid showed broad-spectrum activity against multiple bacterial strains, with strongest effects against Gram-positive organisms including Staphylococcus aureus (Eggert 1997, J Microbiol Biotechnol).
• Tumor growth (in vivo, animal model) — Polysaccharides extracted from the mycelial culture of P. cinnabarinus administered intraperitoneally into white mice at a dosage of 300 mg/kg inhibited the growth of Sarcoma 180 by 90% and Ehrlich solid cancers by 90%, representing substantial antitumor activity in this classic screening model (Ohtsuka et al. 1973).
• Oxidative stress (in vitro) — Fruiting body and mycelium extracts demonstrate antioxidant activity through DPPH radical scavenging, with carotenoid and phenolic compound content contributing to the overall antioxidant capacity.

Secondary (Limited Preclinical Evidence)

• Gram-negative bacterial infections — The 20-day liquid culture filtrate showed antibacterial effects against Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa, though inhibition was generally lower than that observed against Gram-positive organisms.
• Fungal plant pathogen control — Culture filtrates demonstrated antifungal activity against three plant pathogenic fungi in vitro, suggesting potential agricultural as well as medicinal applications.
• Oral infections (ethnomedicinal) — Traditional use by Australian Aboriginal peoples for sore mouths and lips suggests topical antimicrobial application, consistent with the demonstrated antibacterial properties of cinnabarinic acid.

Emerging/Preclinical

• Antiviral applications — General antiviral screening of Polyporaceae species includes P. cinnabarinus, though specific antiviral data for this species is limited compared to other polypores
• Neuroprotective potential — Cinnabarinic acid has been identified as an endogenous ligand for the aryl hydrocarbon receptor (AhR) and the type-4 metabotropic glutamate receptor (mGlu4) in mammalian systems, suggesting potential neuroactive and immunoregulatory roles, though this research pertains to endogenous cinnabarinic acid rather than exogenous supplementation
• Insecticidal activity — Mycelial extracts have demonstrated insecticidal properties, expanding the range of potential bioactive applications

Mechanism of Action

Primary Mechanisms

1. Laccase-catalyzed biosynthesis of cinnabarinic acid: The signature antimicrobial compound of P. cinnabarinus, cinnabarinic acid, is produced through the laccase-mediated oxidation of 3-hydroxyanthranilic acid (3-HAA). The fungal laccase (a multi-copper oxidase, EC 1.10.3.2) catalyzes the oxidative dimerization of 3-HAA through a phenoxazinone synthase-like reaction, producing the phenoxazinone derivative cinnabarinic acid. This is a two-electron oxidation that proceeds through a radical intermediate. The biological activity of concentrated P. cinnabarinus culture fluid is nearly identical to that of purified cinnabarinic acid synthesized by laccase in vitro, confirming that this compound is the primary antibacterial agent produced by the fungus.

2. Cinnabarinic acid-mediated bacterial membrane disruption: Cinnabarinic acid exhibits antibacterial activity primarily against Gram-positive bacteria, with the highest potency against Streptococcus species. The mechanism involves interaction with the bacterial cell membrane and potential inhibition of essential metabolic processes. The preferential activity against Gram-positive over Gram-negative bacteria is consistent with the role of the outer membrane in Gram-negative organisms as a barrier to phenoxazinone compounds. The minimum inhibitory concentrations are in the low micromolar range for susceptible Streptococcus strains.

3. Polysaccharide-mediated immune activation and antitumor effects: Beta-glucan polysaccharides from P. cinnabarinus mycelium activate innate immune cells through pattern recognition receptors, consistent with the general mechanism of fungal polysaccharide immunomodulation. The 90% inhibition of Sarcoma 180 and Ehrlich solid tumors in mice suggests potent immunostimulatory activity mediating indirect antitumor effects through enhanced host immune surveillance, though direct cytotoxic mechanisms cannot be excluded.

Secondary Mechanisms

4. Phenolic acid-mediated antioxidant activity: The fruiting body and mycelium contain multiple phenolic acids (p-benzoic acid, p-phenylacetic acid, o-coumaric acid, ferulic acid, chrysin) that contribute to overall antioxidant capacity through hydrogen atom transfer and electron donation mechanisms. Carotenoid pigments (responsible in part for the vivid orange-red coloration alongside cinnabarinic acid) provide additional lipophilic antioxidant activity.

5. Laccase as a direct bioactive enzyme: Beyond its role in cinnabarinic acid biosynthesis, P. cinnabarinus laccase may have direct bioactive effects. Laccases from related species have demonstrated antiviral activity through oxidative modification of viral surface proteins. The thermostable and pH-stable laccase from P. cinnabarinus is particularly robust, maintaining activity across a wide range of conditions.

6. Carotenoid-mediated photoprotection and antioxidant effects: The carotenoid content of P. cinnabarinus is notable among polypore fungi and contributes to singlet oxygen quenching and lipid peroxidation prevention. These compounds may contribute to the traditional topical use for oral conditions through local tissue protection.

Clinical Evidence Summary

No human clinical trials have been conducted with Pycnoporus cinnabarinus. Evidence is entirely preclinical, with the antimicrobial pathway being the most thoroughly characterized.

Key Preclinical Studies

Evidence Limitations

• No human clinical trials or formal toxicology studies
• The Sarcoma 180 mouse model, while historically important for screening, uses intraperitoneal injection of polysaccharides, which does not reflect oral bioavailability
• Antibacterial activity has been demonstrated primarily in vitro; in vivo efficacy and pharmacokinetics of cinnabarinic acid are not established
• P. cinnabarinus has been studied more extensively as a biotechnology organism (laccase production, lignin degradation) than as a medicinal mushroom, creating a knowledge gap in pharmacological characterization
• The relationship between P. cinnabarinus (temperate) and P. sanguineus (tropical) has been revised through molecular phylogenetics; some older literature may conflate the two species
• No dose-response studies in humans or large animal models
• Antitumor polysaccharide data dates to the 1970s and has not been replicated with modern methodologies

Safety Profile

General Assessment

Pycnoporus cinnabarinus is not known to be toxic. It is classified as inedible due to its tough, corky texture rather than any known harmful effects. Traditional use by Australian Aboriginal peoples for oral conditions suggests a history of topical human exposure without adverse effects. The lack of formal toxicology studies means that safety in humans is not fully characterized, though the long history of ecological co-existence and limited ethnomedicinal use provides some reassurance.

Contraindications

• Known allergy to mushrooms (Basidiomycota): Standard precaution for all medicinal mushroom preparations
• Pregnancy and lactation: No reproductive safety data available; avoid until safety is established
• Individuals on antibiotic therapy: Potential for additive or unpredictable interactions with the antimicrobial cinnabarinic acid, though this is theoretical

Drug Interactions

• No documented drug interactions in humans
• Theoretical concern for additive effects with antibiotics, particularly those targeting Gram-positive organisms, due to the antibacterial activity of cinnabarinic acid
• Laccase enzymes can oxidize a wide range of substrates including phenolic drugs; theoretical concern for modification of orally co-administered phenolic compounds, though this would require intact laccase enzyme activity in the gastrointestinal tract

Side Effects

• No side effects documented in the literature due to absence of human clinical use
• The fruiting body is not consumed as food due to its tough, corky texture
• Traditional topical use for oral conditions does not report adverse effects

Toxicology

• No formal toxicology studies published
• Cinnabarinic acid is structurally related to phenoxazinone antibiotics (e.g., actinomycin D chromophore), but lacks the peptide moiety responsible for the severe toxicity of actinomycin D; the structural relationship should not imply comparable toxicity
• Polysaccharide fractions showed antitumor activity at 300 mg/kg IP in mice without reported toxicity, suggesting a reasonable therapeutic index at this dose

Clinical Dosage

No clinically validated dosage exists for Pycnoporus cinnabarinus due to the complete absence of human trials.

Experimental Dosages (Preclinical Research)

• Mycelial polysaccharides (animal model): 300 mg/kg body weight administered intraperitoneally in mice for antitumor activity (Ohtsuka et al. 1973); this route does not translate directly to oral dosing
• Cinnabarinic acid (in vitro): Antibacterial activity observed at concentrations in the low micrograms/mL range; minimum inhibitory concentrations vary by bacterial strain
• Culture filtrate: 20-day liquid culture filtrate used directly in antimicrobial assays; concentration varies by culture conditions

Traditional Preparation

• Australian Aboriginal use: Applied topically to sore mouths and lips; specific preparation methods are not well documented in the ethnobotanical literature
• Decoction: Like other tough polypores, P. cinnabarinus could theoretically be prepared as a prolonged decoction (2-4 hours simmering), though this specific preparation is not documented for this species

Product Quality Considerations

• No commercial supplements of Pycnoporus cinnabarinus are widely available
• Cinnabarinic acid content depends on laccase activity, which is influenced by culture conditions, substrate composition, and copper availability
• The vivid orange-red coloration of fresh fruiting bodies correlates with cinnabarinic acid content, though quantitative standardization methods are not commercially established
• Research-grade laccase preparations are available from P. cinnabarinus but are intended for biotechnological rather than medicinal applications

Sources

• Eggert C, Temp U, Eriksson KE. Laccase-catalyzed formation of cinnabarinic acid is responsible for antibacterial activity of Pycnoporus cinnabarinus. J Microbiol Biotechnol. 1997;7(4):227-231
• Ohtsuka S, Ueno S, Yoshikumi C, et al. Polysaccharides having an anticarcinogenic effect and a method of producing them from species of Basidiomycetes. UK Patent 1331513. 1973
• Lomascolo A, Stentelaire C, Asther M, Lesage-Meessen L. Basidiomycetes as new biotechnological tools to generate natural aromatic flavours for the food industry. Trends Biotechnol. 1999;17(7):282-289
• Borderes J, Costa A, Guedes A, Tavares LBB. Stimulation of cinnabarinic acid production in batch cultures of Pycnoporus cinnabarinus. Braz J Chem Eng. 2011;28(2):199-206
• Smolskiene G, Vaitiekunaite V, Bridziuviene D. Enzymatic, antioxidant, antimicrobial, and insecticidal activities of Pleurotus pulmonarius and Pycnoporus cinnabarinus grown separately in an airlift reactor. BioResources. 2015;10(2):2894-2906
• Temp U, Eggert C. Novel interaction between laccase and cellobiose dehydrogenase during pigment synthesis in the white rot fungus Pycnoporus cinnabarinus. Appl Environ Microbiol. 1999;65(2):389-395
• Levasseur A, Lomascolo A, Chabrol O, et al. The genome of the white-rot fungus Pycnoporus cinnabarinus: a basidiomycete model with a versatile arsenal for lignocellulosic biomass breakdown. BMC Genomics. 2014;15:486
• Acosta-Urdapilleta ML, Medrano-Vega F, Villegas E, Garibay-Orijel R. Pycnoporus sanguineus and cinnabarinus — a review of biology and applications. Mycosphere. 2021;12(1):1-49
• Dias DA, Urban S. Phytochemical analysis of the southern Australian marine alga, Plocamium mertensii using HPLC-NMR. Phytochem Anal. 2008;19(5):453-470

Connections

• Closely related to Turkey Tail (Trametes versicolor) within the Polyporaceae; both produce laccase enzymes, but P. cinnabarinus is distinguished by its unique cinnabarinic acid antimicrobial pigment pathway
• Compare with Trametes hirsuta and Trametes robiniophila, other Trametes-allied polypores with documented medicinal properties; P. cinnabarinus is phylogenetically close to the Trametes clade
• The laccase-mediated antimicrobial mechanism is unique among medicinal polypores and represents a fundamentally different mode of action from the polysaccharide-based immunomodulation seen in most medicinal mushrooms including Reishi and Maitake
• The Sarcoma 180 antitumor screening result (90% inhibition) places P. cinnabarinus polysaccharides among the most potent in the classic polypore polysaccharide screening literature, comparable to results from Schizophyllum commune and Turkey Tail
• P. cinnabarinus is the temperate counterpart of the tropical P. sanguineus, and research findings on one species may be partially applicable to the other, though chemical profiles differ between the two
• The biotechnological importance of P. cinnabarinus laccase (lignin degradation, bioremediation, dye decolorization) far exceeds its current medicinal applications, representing an untapped opportunity for medicinal development from an already well-characterized organism